S&P 5007,713▲ 0.28%Nasdaq26,425▼ 0.02%Dow Jones52,496▲ 1.02%Nasdaq 10029,490▼ 0.13%VIX17.31▼ 6.13%US Dollar101.73▼ 0.25%Gold spot4,145▲ 0.30%WTI spot101.91▲ 1.04%
London Exchange · UK · Updated after 20 Oct 2026 close

Bavarian Nordic A/S

0DPB · London Exchange · prices in DKK
DKK 242.40▲ +5.30 (2.24%)
Research reportHistorical data

About Bavarian Nordic A/S

Bavarian Nordic is a vaccine company based in Denmark. It develops and manufactures vaccines for infectious diseases, including a smallpox and monkeypox vaccine supplied to governments and public health authorities. The company also provides contract manufacturing services, producing vaccines on behalf of other pharmaceutical firms. Its customers are mainly government agencies, public health bodies and healthcare organisations that stockpile or distribute vaccines, and its work spans research, clinical development and commercial production at its own facilities.

The shares are listed on the London Exchange in UK under the code 0DPB, and the price on this page is in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

61/ 100
Market X-Ray · price-based
Fair price profile
Ranks #1240 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendStrong
85/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average20.6%
From 52-week high0.0%
MomentumFair
69/100
Typical recent returns for this exchange.
See the numbers →
3-month return34.1%
6-month return24.9%
12-month, skipping last month-12.5%
Stability (higher is calmer)Weak
28/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)119.4%
Worst drawdown, 1 year (smaller is calmer)-28.3%
LiquidityFair
64/100
Moderate trading activity.
See the numbers →
Avg daily value traded3.19M DKK
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
Price trend
Uptrend
Versus its 50- and 200-day averages
52-week range
171.60 – 242.40
Price is 100% of the way up
Returns
+34.1% 3m · +0.6% 1y
Price returns, dividends not included
RSI (14)
71
Overbought zone

Price chart

52-wk range 171.60 – 242.40 Daily closes, split-adjusted

Signals

50-day average213.68
200-day average200.93
Golden/death cross (60d)Golden, 12 days ago
New 52-week highYes
Bullish RSI divergenceNo
Average daily range (ATR)15.00

Technical summary

Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
SMA 10236.2Bullish
EMA 10235.3Bullish
SMA 20228.0Bullish
EMA 20229.0Bullish
SMA 50213.7Bullish
EMA 50216.0Bullish
SMA 100197.4Bullish
EMA 100206.8Bullish
SMA 200200.9Bullish
EMA 200203.2Bullish
Oscillators (daily)
RSI (14)71.41Bearish
MACD (12, 26)8.20Bullish
Momentum (12)12.12Bullish
Stochastic %K (14)100.0Bearish
Williams %R (14)0.00Bearish
CCI (20)-23.80Neutral
Pivot points (classic, last session)
S3
143.1
S2
162.9
S1
202.7
Pivot
222.5
R1
262.3
R2
282.1
R3
321.9
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in DKK. Educational only, not financial advice.